New Fast-Acting insulin pump treatment shows promise for type 2 diabetes
NCT ID NCT07068295
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new fast-acting insulin called NNC0471-0119 in 65 adults with type 2 diabetes who use an insulin pump. Researchers compared how quickly the new insulin enters the bloodstream and lowers blood sugar versus a standard insulin (insulin aspart). The goal is to see if the new insulin works faster and is safe for pump use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NNC0471-0119 (a fast-acting insulin) and insulin aspart (comparator)
What this could lead to
If successful, this could lead to a faster-acting insulin option for insulin pumps, potentially improving blood sugar control after meals for people with type 2 diabetes.
What could go wrong
This is an early phase 1 study with only 65 participants, so results may not apply to everyone. The new insulin may not work better or could have unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS (TYPE 2) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Profil Institut für Stoffwechselforschung GmbH
Neuss, 41460, Germany